Brolucizumab
Generic Details
Generic Name
Brolucizumab
Other Names
- Beovu
Drug Class
- Anti-VEGF monoclonal antibody
Chemical Formula
C6364H9878N1696O2018S46
Molecular Weight
144190.6 g/mol
Mechanism of Action
- Inhibition of vascular endothelial growth factor (VEGF)
Indications
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Common Dosage Forms
- Intravitreal injection
Typical Dosage
- Single dose of 6 mg
Pediatric Dosage
Geriatric Dosage
Side Effects
- Eye pain
- Blurred vision
- Increased intraocular pressure
- Conjunctival hemorrhage
Contraindications
- Hypersensitivity to brolucizumab or any component of the formulation
Pregnancy Category
- Category C - Animal reproduction studies have shown an adverse effect on the fetus
Lactation Safety
- Unknown if excreted in breast milk, use caution
Drug Interactions
- No specific drug interactions reported
Overdose Symptoms
Antidote for Overdose
Storage Conditions
- Refrigerate at 2-8°C (36-46°F)
- Do not freeze
Pharmacokinetics
- Absorption: Absorption following intravitreal injection
- Distribution: Limited systemic distribution
- Metabolism: Metabolized to small peptides and amino acids
- Excretion: Elimination primarily through proteolytic degradation
Precautions
- Monitor for signs of endophthalmitis following injection
Warnings
- Potential for arterial thromboembolic events